Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC006 combined with tislelizumab in recurrent or metastatic non-small cell lung cancer
ChiCTR2100042125Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ACC006 and tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Dose-limiting toxicity. Started Oct 2020; status: recruiting.
02
Drugs
ACC006tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100042125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042125.